Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

Rhea-AI Summary

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022. The fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET, featuring President and CEO Ian Mortimer and CCO Chris Von Seggern as presenters. A webcast will be available in the 'Investors' section of Xenon's website, with replays posted afterward. Xenon focuses on developing therapeutics for neurological disorders, particularly epilepsy.

News Market Reaction – XENE

-1.34%

-1.34% Session move

In the trading session that priced this news, XENE declined 1.34%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.

Fireside Chat Details:

	Date:	Thursday, September 8, 2022
	Time:	11:35 am -12:05 pm ET
	Presenters:	Ian Mortimer, President and CEO Chris Von Seggern, CCO

A webcast of the fireside chat will be available on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

FAQ

When will Xenon Pharmaceuticals participate in the Wells Fargo Securities Healthcare Conference?

Xenon Pharmaceuticals will participate in the Wells Fargo Securities Healthcare Conference from September 7-9, 2022.

What is the schedule for Xenon's fireside chat at the conference?

Xenon's fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET.

Who will present during Xenon's fireside chat?

The presenters during Xenon's fireside chat will be President and CEO Ian Mortimer and CCO Chris Von Seggern.

Where can I watch the webcast of Xenon's fireside chat?

The webcast of Xenon's fireside chat will be available in the 'Investors' section of their website.

What is the focus of Xenon Pharmaceuticals?

Xenon Pharmaceuticals focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy.